VEGFA and renal cell carcinoma: In addition, evidence from renal cell carcinoma suggests that VEGF pathway inhibitors can directly alter intestinal homoeostasis,18 highlighting how ATB may plausibly alter a complex bidirectional relationship between TKI therapy and survival by acting synergistically on composition and function of the gut microbiome.